Decision Resources, Inc., Oct 2011
, with the possibility of a further 90 days for reimbursement decision making. What are the average delays to market access in price-regulated markets? What are the pharmaceutical industry’s concerns and aspirations
Decision Resources, Inc., Oct 2011
diseases and drug-treatment rates in the seven majorpharmaceuticalmarkets in 2010 and 2020.
Pharmaceuticalpricing: Procedures for setting prices; use of external reference pricing.
Admission
Just Pharma Reports, June 2011, Pages: 143
-selling 2008 report, and the author’s fifth major title on orphan drugs.
Updated to May 2011, it includes:
- Availability, price and reimbursement status for all 60 EU-designated orphan drugs
Cutting Edge Information, Aug 2009, Pages: 123
system. Interviewed pharmaceutical executives discuss their strategic responses to potential changes that could be on the managed markets horizon. Cutting Edge Information's analysts designed the practices
Decision Resources, Inc., March 2011, Pages: 70
in this report:
- The United States has the highest overall prescription drug prices of any of the majorpharmaceuticalmarkets. How do the prices of metabolic disease therapies in Europe and Japan compare
Arrowhead Publishers, March 2006, Pages: 209
strategies
- In-depth information regarding the pricing environments of the American, European and Japanese pharmaceuticalmarkets, comparing and contrasting their major features with a view to securing
Datamonitor, Oct 2011, Pages: 35
Governments across the five major EU markets (France, Germany, Italy, Spain, and the UK) have been busy implementing regulatory, pricing, and reimbursement reforms in 2011. Price cuts have impacted
Decision Resources, Inc., July 2010, Pages: 40
Summary
Strategic Considerations
Stakeholder Implications
Overview
Organization and Funding of the Japanese Healthcare System
Healthcare Expenditures
PharmaceuticalPrices in Japan
Price Setting
Decision Resources, Inc., May 2008, Pages: 30
Prices, 2006
3 Prices of Leading Biologics in the MajorMarkets as a Percentage of US Prices
4 PharmaceuticalReimbursement Categories in Italy
5 Targets of Key Pharmaceutical Cost-Containment Measures
Decision Resources, Inc., June 2011
Healthcare Dynamics in Emerging Markets
Brazil
Healthcare Infrastructure
Pharmaceutical Funding and Reimbursement
Factors Influencing PharmaceuticalPricing
Russia
Healthcare Infrastructure
Decision Resources, Inc., Aug 2008, Pages: 34
payers. The National Pricing and Reimbursement Series analyzes the evolving pricing and reimbursement environment in seven majormarkets (the United States, France, Germany, Italy, Spain
Decision Resources, Inc., March 2008, Pages: 70
Stakeholder Implications
Overview
Organization and Funding of the German Health Care System
PharmaceuticalPrices in Germany
Reimbursement of Outpatient Medicines
Cost-Containment
Reference Pricing
Decision Resources, Inc., June 2008, Pages: 45
Biologics in the MajorMarkets as a Percentage of U.S. Prices, 2006
4. Relationship Between SMR Ratings and Reimbursement Rates by Disease Severity
5. Targets of Key Pharmaceutical Cost-Containment Measures
Decision Resources, Inc., Dec 2007, Pages: 32
Introduction
The third quarter of 2007 was a quiet period in terms of legislation and other major developments in pricing and reimbursement in the majorpharmaceuticalmarkets, but recent trends
Decision Resources, Inc., Aug 2009, Pages: 40
for new drugs; prescribing and reimbursement restrictions; growth of flexible pricing arrangements. Executive Summary
- Strategic Considerations
- Stakeholder Implications
Overview
United States
Decision Resources, Inc., Jan 2010, Pages: 30
in Germany? What question has been raised with regard to rebate contracts?
- The United Kingdom has gone from being one of the highest-pricedpharmaceuticalmarkets in Europe to the lowest-priced
Decision Resources, Inc., April 2008, Pages: 43
in the United Kingdom: the PharmaceuticalPrice Regulation Scheme
Key Developments in the First Quarter of 2008
- Reductions in Medicare Hospital Outpatient Reimbursement
- European Commission Launches Major Antitrust
Decision Resources, Inc., Sep 2011
In the second quarter of 2011, several governments in majorpharmaceuticalmarkets announced plans for important regulatory changes or new cost-containment measures, while other governments
